PembroWM now open to recruitment
15 October 2019
A new trial for patients with Waldenström’s macroglobulinaemia (PembroWM) opened to recruitment in September at the following hospitals: Derriford, Churchill, Royal Bournemouth and UCLH. The trial is run by the CR UK & UCL Cancer Trials Centre and is supported by Merck, Sharp and Dohme Ltd. 

PembroWM is a single arm, phase II trial that will recruit patients who have previously been treated for Waldenström’s macroglobulinaemia whose disease has not responded or returned. These patients will receive a combination of two immunotherapy drugs, Rituximab and Pembrolizumab, which stimulate the body’s immune system to fight cancer cells. The main aim of the trial is to investigate whether the combination of Rituximab and Pembrolizumab is a safe and effective drug combination for this disease. 

The trial is a national study which requires 42 patients to take part. It will open in 8 UK sites. PembroWM is due to complete recruitment in 2021.
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road

View map
+44 (0)20 7679 9898 (General CTC Enquiries)
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2024 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us